Inmunotek S.l.
Clinical trials sponsored by Inmunotek S.l., explained in plain language.
-
New allergy shots show promise for dust mite sufferers
Disease control CompletedThis study tested a type of allergy immunotherapy (Clustoid® Max Forte) in 140 people aged 5 to 65 with dust mite allergies. The goal was to see if it reduces allergy and asthma symptoms and the need for medication over one year. Results were measured by symptom scores and medica…
Sponsor: Inmunotek S.L. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Could a daily Under-the-Tongue vaccine tame COPD flare-ups?
Disease control CompletedThis study tested whether a bacterial vaccine called MV130, taken daily under the tongue for 12 months, can reduce the number and severity of COPD flare-ups in adults with moderate to severe COPD. A total of 198 participants were randomly assigned to receive either MV130 or a pla…
Phase: PHASE2, PHASE3 • Sponsor: Inmunotek S.L. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Grass allergy test study seeks better standardization
Knowledge-focused CompletedThis study aimed to find the right strength of two grass allergen extracts (timothy and orchard grass) to cause a skin reaction similar to histamine. Thirty-one adults with grass pollen allergies received skin prick tests with different concentrations. The goal was to improve all…
Phase: NA • Sponsor: Inmunotek S.L. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC